Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 772Leukemia 596Leukemia, Lymphocytic, Chronic, B-Cell 535Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Myelodysplastic Syndromes 408Lymphoma, Non-Hodgkin 265Lymphoma 265Hematologic Neoplasms 251Leukemia, Myelogenous, Chronic, BCR-ABL Positive 232Multiple Myeloma 199Hodgkin Disease 193Lymphoma, Follicular 181Lymphoma, Mantle-Cell 179Lymphoma, B-Cell, Marginal Zone 156Lymphoma, Large B-Cell, Diffuse 155Burkitt Lymphoma 155Recurrence 149Leukemia, Myelomonocytic, Chronic 139Congenital Abnormalities 131Myeloproliferative Disorders 122Waldenstrom Macroglobulinemia 106Neoplasms 97Leukemia, Myeloid, Chronic-Phase 97Lymphoma, Large-Cell, Immunoblastic 91Primary Myelofibrosis 88Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81Blast Crisis 80Leukemia, Myeloid, Accelerated Phase 74Anemia, Refractory, with Excess of Blasts 72Lymphoma, T-Cell, Cutaneous 68

Interventions

Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Herpes Zoster × Other hematologic neoplasm × Clear all
NCT03702231 2023-08-04

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
116 enrolled 11 charts
LymphoidOther hematologic neoplasm

Herpes Simplex, Herpes Zoster, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01254630 2019-09-30

V212-011

Merck Sharp & Dohme LLC

Phase 3 Completed
5,305 enrolled 20 charts
Other hematologic neoplasm

Herpes Zoster, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡